Inhibrx Inc
NASDAQ:INBX
Inhibrx Inc
Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The company is headquartered in La Jolla, California and currently employs 106 full-time employees. The company went IPO on 2020-08-19. The Company’s single domain antibody (sdAb) platform provides a small, simple, modular target binding domain that can be combined in to meet the needs of each biological target. Its products pipeline includes: INBRX-101 is a recombinant alpha-1 antitrypsin (AAT) protein that is comprised of two human AAT, molecules covalently linked to the fragment crystallizable (Fc) region of human immunoglobulin G4; INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate targeting death-receptor 5 (DR5) that designed with its sdAb platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis, and INBRX-105 is a precisely engineered multi-specific sdAb-based therapeutic candidate that is designed to agonize 4-1BB selectively in the presence of PD-L1.
Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The company is headquartered in La Jolla, California and currently employs 106 full-time employees. The company went IPO on 2020-08-19. The Company’s single domain antibody (sdAb) platform provides a small, simple, modular target binding domain that can be combined in to meet the needs of each biological target. Its products pipeline includes: INBRX-101 is a recombinant alpha-1 antitrypsin (AAT) protein that is comprised of two human AAT, molecules covalently linked to the fragment crystallizable (Fc) region of human immunoglobulin G4; INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate targeting death-receptor 5 (DR5) that designed with its sdAb platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis, and INBRX-105 is a precisely engineered multi-specific sdAb-based therapeutic candidate that is designed to agonize 4-1BB selectively in the presence of PD-L1.
